This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Company News for Jan 8, 2025
by Zacks Equity Research
Companies In The News Are: RPM, LNN, TSLA, MRNA.
LNNNegative Net Change MRNANegative Net Change TSLANegative Net Change RPMNegative Net Change
auto-tires-trucks biotechnology construction industrial-products
Denali's ALS Study Fails to Meet Primary and Secondary Endpoints
by Zacks Equity Research
DNLI's DNL343 fails to achieve the primary and secondary endpoints, as observed from an analysis of Regimen G of the phase II/III HEALEY ALS platform trial.
SNYPositive Net Change BIIBNegative Net Change DNLINegative Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use
by Zacks Equity Research
EC expands the label of Ultragenyx's Evkeeza in the EU to treat younger patients aged 6 months to 5 years suffering from a rare cholesterol disorder.
REGNPositive Net Change VNDAPositive Net Change RAREPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?
by Zacks Equity Research
EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabometyx. We are optimistic about the stock as we believe there is room for further growth.
BMYNegative Net Change MRKPositive Net Change EXELPositive Net Change
biotechnology biotechs medical pharmaceuticals
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates
by Zacks Equity Research
Kodiak stock skyrockets 271% in six months on the back of positive updates from the tarcocimab program for treating retinal vascular diseases.
VNDAPositive Net Change CTMXNegative Net Change KODPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Beat the Market the Zacks Way: SoFi Technologies, Lisata Therapeutics, AutoZone in Focus
by Santanu Roy
Our time-tested methodologies helped investors navigate the market well last week. Here are some of our key performance data from the past three months.
ADPNegative Net Change DGXNegative Net Change DISNegative Net Change AZONegative Net Change IDCCNegative Net Change LNGPositive Net Change COHRNegative Net Change FIPositive Net Change NOBLNegative Net Change ATGENegative Net Change SOFINegative Net Change LSTANegative Net Change
biotechnology business-services communications consumer-discretionary finance medical retail
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug
by Zacks Equity Research
Mesoblast stock climbs 80% in a month following the FDA's approval of Ryoncil as the only approved therapy for SR-aGVHD in children aged two months and older.
MESOPositive Net Change CTMXNegative Net Change SPROPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
by Zacks Equity Research
Capricor stock gains 8% upon completing the rolling submission of the BLA for its lead asset, deramiocel, to treat DMD cardiomyopathy in the United States.
CAPRNegative Net Change CTMXNegative Net Change SPROPositive Net Change CSTLPositive Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
Braze, Inc. (BRZE) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
BRZENegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
by Zacks Equity Research
Monopar stock skyrockets 384% in three months following a licensing deal with AstraZeneca for a late-stage Wilson Disease candidate.
AZNPositive Net Change SPROPositive Net Change CSTLPositive Net Change MNPRPositive Net Change
biotechnology biotechs medical pharmaceuticals
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag
by Zacks Equity Research
The FDA accepts Verastem's NDA for the accelerated approval of avutometinib to treat recurrent KRAS mutant ovarian cancer under priority review. The stock rises 41%.
VSTMNegative Net Change CTMXNegative Net Change SPROPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Company News for Jan 2, 2025
by Zacks Equity Research
Companies In The News Are: X, BHVN, SGMO, PFE, BLDR.
PFENegative Net Change BLDRNegative Net Change SGMOPositive Net Change BHVNNegative Net Change
basic-materials biotechnology construction
Corcept Submits Application for Another Cushing's Syndrome Drug
by Zacks Equity Research
CORT makes pipeline progress with the submission of a new drug application for relacorilant to treat patients with endogenous hypercortisolism.
BMYNegative Net Change RIGLPositive Net Change CORTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
by Zacks Equity Research
NVS' phase III study on experimental gene therapy candidate Intrathecal onasemnogene abeparvovec (OAV101IT) meets its primary goal.
NVSPositive Net Change PTCTPositive Net Change OLMANegative Net Change
biotechnology biotechs medical pharmaceuticals
Best Momentum Stocks to Buy for December 30th
by Zacks Equity Research
CCRD, TRDA and NRXP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 30, 2024.
NRXPPositive Net Change TRDANegative Net Change CCRDNegative Net Change
biotechnology
JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723
by Zacks Equity Research
Johnson & Johnson announces a global licensing deal with Kaken for the latter's eczema candidate, KP-723, to further strengthen its dermatology portfolio.
JNJPositive Net Change CTMXNegative Net Change SPROPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
by Ahan Chakraborty
Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025.
MESOPositive Net Change KODPositive Net Change MNPRPositive Net Change ARQTPositive Net Change
biotechnology biotechs cell-therapy medical oncology-screening pharmaceuticals
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex
by Zacks Equity Research
ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex are part of the Zacks top Analyst Blog.
ADMANegative Net Change STOKPositive Net Change TARSPositive Net Change
biotechnology medical
Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do?
by Ahan Chakraborty
NVO stock declines after a recent obesity study setback and intense competition from market rivals but offers long-term growth potential.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
AZN's Tagrisso Gets Approval in the EU for Expanded Use in NSCLC
by Zacks Equity Research
AstraZeneca wins approval in the EU for the label expansion of Tagrisso to treat adult patients with locally advanced, unresectable NSCLC.
AZNPositive Net Change CTMXNegative Net Change SPROPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III
by Zacks Equity Research
Novo Nordisk stock slumps as the 22.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in a phase III study misses its guidance of 25%.
NVOPositive Net Change MRKPositive Net Change LLYPositive Net Change AMGNPositive Net Change
biotechnology biotechs medical pharmaceuticals
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term
by Nalak Das
These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL.
RIGLPositive Net Change CRSPPositive Net Change CSTLPositive Net Change IMCRPositive Net Change GLUENegative Net Change
biofuels biotechnology
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?
by Ekta Bagri
GILD has put up a steady performance in 2024, with a new drug approval, positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.
GSKPositive Net Change MRKPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Intellia Crashes 60% in a Year: How Should You Play the Stock?
by Ekta Bagri
NTLA stock is down significantly in 2024 as investors are not pleased with the recent data from its in vivo CRISPR-based therapies. We advise prospective investors to stay on the sidelines for now.
REGNPositive Net Change IONSNegative Net Change NTLANegative Net Change CRSPPositive Net Change
biotechnology biotechs gene-editing genomics pharmaceuticals
RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy
by Zacks Equity Research
Ultragenyx submits a BLA to the FDA seeking the accelerated approval of UX111 for patients with Sanfilippo syndrome type A in the United States.
RAREPositive Net Change CTMXNegative Net Change SPROPositive Net Change CSTLPositive Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals